Scandion Oncology has announced the outcome of a rights issue of up to SEK93.7m. At the end of the subscription period (1 July 2022), approximately 80% of the rights issue has been subscribed, including c 66.5% from guarantors. Management has communicated that it has raised c SEK75m gross, which we estimate will result in a net cash injection of c SEK58m based on estimated transaction costs of SEK17m that were previously announced. Management will now register the rights issue with Danish author ....
05 Jul 2022
Scandion Oncology - Outcome of rights issue
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Scandion Oncology - Outcome of rights issue
- Published:
05 Jul 2022 -
Author:
Soo Romanoff -
Pages:
2
Scandion Oncology has announced the outcome of a rights issue of up to SEK93.7m. At the end of the subscription period (1 July 2022), approximately 80% of the rights issue has been subscribed, including c 66.5% from guarantors. Management has communicated that it has raised c SEK75m gross, which we estimate will result in a net cash injection of c SEK58m based on estimated transaction costs of SEK17m that were previously announced. Management will now register the rights issue with Danish author ....